Gem Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Gem Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011827
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Gem Pharmaceuticals LLC (Gem Pharmaceuticals) is a clinical-stage biopharmaceutical company that develops proprietary anthracycline derivatives. The company’s pipeline products include GPX-150 for oncology, topical GPX-150 for inflammation, GPX 150 oral formulations and potency analogues programs, and non-cardiotoxic versions of other anthracyclines. It uses proprietary chemical modification platform to generate non-cardiotoxic and generally less toxic versions of all anthracyclines. Gem Pharmaceuticals develops drugs for treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, transplant and other T-cell mediated disorders. The company’s products are used to eliminate cardiotoxicity side effect in chemotherapeutics. Gem Pharmaceuticals is headquartered in Birmingham, Alabama, the US.

Gem Pharmaceuticals LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Gem Pharma To Raise US$4.5 Million In Venture Financing 10
Partnerships 11
OncBioMune Pharma to Enter into Agreement with Gem Pharma 11
Asset Transactions 12
Monopar Therapeutics Acquires GPX-150 from Gem Pharma 12
Gem Pharmaceuticals LLC – Key Competitors 13
Gem Pharmaceuticals LLC – Key Employees 14
Gem Pharmaceuticals LLC – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gem Pharmaceuticals LLC, Deals By Therapy Area, 2011 to YTD 2017 8
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gem Pharma To Raise US$4.5 Million In Venture Financing 10
OncBioMune Pharma to Enter into Agreement with Gem Pharma 11
Monopar Therapeutics Acquires GPX-150 from Gem Pharma 12
Gem Pharmaceuticals LLC, Key Competitors 13
Gem Pharmaceuticals LLC, Key Employees 14

★海外企業調査レポート[Gem Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■

◆H&Iグローバルリサーチ株式会社のお客様(例)◆